## RESPONSE UNDER 37 C.F.R. §1.116 EXPEDITED PROCEDURE GROUP ART UNIT 1647

Dkt. 0575/66602-B/JPW/BJA/LM

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Silviu Itescu

U.S. Serial No. : 10/693,480 Group Art Unit:1635

Filed : October 23, 2003 Examiner: B. E. Bunner

For : REGENERATION OF ENDOGENOUS MYOCARDIAL

TISSUE

30 Rockefeller Plaza, 20<sup>th</sup> Fl. New York, New York 10112 August 3, 2009

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA, 22313-1450

Sir:

0 e 5000

COMMUNICATION IN RESPONSE TO
FEBRUARY 3, 2009 FINAL OFFICE ACTION
AND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AS SUBMISSIONS UNDER 37 C.F.R. §1.114(C)
TO THE ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION
AND PETITION FOR THREE-MONTH EXTENSION OF TIME

This Communication is a submission under 37 C.F.R. §1.114(c) to the accompanying Request for Continued Examination (RCE) and responds to the rejections made in the February 3, 2009 Final Office Action issued by the United States Patent and Trademark Office in connection with the above-identified application. A response to the February 3, 2009 Final Office Action was due May 3, 2009. Applicant hereby petitions for a three-month extension of time. The fee for a three-month extension of time is FIVE HUNDRED AND FIFTY FIVE DOLLARS (\$555.00) for a small entity and a check including this amount is enclosed. With a three-month extension of time a response is now due August 3, 2009. Accordingly, the RCE, this

08/07/2009 HVUDNG1 00000015 10693480

02 FC:2253

555.00 OP

Applicant : Silviu Itescu U.S. Serial No. : 10/693,480

Filed : October 23, 2003

Page 2 of 15 - Communication in Response to February 3, 2009 Final Office Action and Supplemental Information Disclosure Statement as Submissions Under 37 C.F.R. §1.114(C) to the Accompanying Request for Continued Examination and Petition for Three-Month Extension of Time

Communication and the Supplemental Information Disclosure Statement as submissions to accompany the RCE are being timely filed.

Remarks begin on page 3 of this paper.

A Supplemental Information Disclosure Statement begins on page 10 of this paper.